William Blair Issues Pessimistic Estimate for BRNS Earnings

Barinthus Biotherapeutics plc (NASDAQ:BRNS) – Investment analysts at William Blair reduced their FY2025 EPS estimates for shares of Barinthus Biotherapeutics in a note issued to investors on Wednesday, May 7th. William Blair analyst A. Hsieh now expects that the company will post earnings of ($1.63) per share for the year, down from their previous estimate of ($1.52). The consensus estimate for Barinthus Biotherapeutics’ current full-year earnings is ($1.38) per share. William Blair also issued estimates for Barinthus Biotherapeutics’ FY2026 earnings at ($1.69) EPS.

Barinthus Biotherapeutics (NASDAQ:BRNS) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.15).

A number of other equities analysts also recently weighed in on BRNS. HC Wainwright reiterated a “buy” rating and issued a $3.00 target price on shares of Barinthus Biotherapeutics in a report on Friday, March 21st. Alliance Global Partners reiterated a “buy” rating on shares of Barinthus Biotherapeutics in a research report on Monday, March 24th.

Barinthus Biotherapeutics Trading Down 3.7%

Shares of Barinthus Biotherapeutics stock opened at $0.87 on Monday. Barinthus Biotherapeutics has a 1 year low of $0.64 and a 1 year high of $2.44. The company has a market cap of $34.97 million, a P/E ratio of -0.58 and a beta of -0.80. The stock has a 50-day moving average price of $0.89 and a 200 day moving average price of $1.01.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Barinthus Biotherapeutics stock. Gilead Sciences Inc. purchased a new stake in shares of Barinthus Biotherapeutics plc (NASDAQ:BRNS) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 620,351 shares of the company’s stock, valued at approximately $749,000. Barinthus Biotherapeutics comprises approximately 0.0% of Gilead Sciences Inc.’s holdings, making the stock its 14th biggest position. Gilead Sciences Inc. owned approximately 1.54% of Barinthus Biotherapeutics as of its most recent filing with the Securities and Exchange Commission. 25.20% of the stock is owned by institutional investors.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.